Abstract 31P
Background
Breast edema is defined as a high signal intensity on T2-weighted magnetic resonance imaging (MRI), and it is an essential image phenotype of breast MRI. The purpose of this study was to investigate the prognostic implication of breast edema on preoperative breast MRI in breast cancer patients.
Methods
We retrospectively analyzed the data of 899 breast cancer patients at a single institution. Patients were divided into the edema-positive group (EPG) and the edema-negative group (ENG) according to the presence of breast edema on preoperative breast MRI. We compared the clinicopathologic characteristics and the survival outcomes between the two groups. A two-sample t-test was used to determine statistical differences between mean ages, and Pearson’s χ2 test was used to determine statistical differences between all the other baseline characteristics. The log-rank test was used to compare the survival curves from Kaplan–Meier estimator. The Cox proportional hazards model was used to calculate the hazard ratio (HR) and 95% confidence interval (CI).
Results
There were 399 (44.4%) patients in the EPG and 500 (55.6%) patients in the ENG. Among patients in the EPG, peritumoral, prepectoral, and subcutaneous edemas were present in 387, 130, and 66 patients, respectively. EPG showed significantly higher rates of axillary lymph node metastasis (55.6% vs. 19.2%, p < 0.001) and lymphovascular invasion (LVI) (57.9% vs. 12.6%, p < 0.001) than ENG. Patients in the EPG showed significantly worse overall survival rate (log-rank p < 0.001; HR: 4.83; 95% CI: 2.56-9.11) and recurrence-free survival rate (log-rank p < 0.001; HR: 3.00; 95% CI: 1.94-4.63) than those in the ENG. After adjusting for other variables, breast edema still remained a significant factor affecting overall survival rate regardless of edema type.
Conclusions
Breast edema on preoperative breast MRI is strongly correlated with several clinicopathological features including nodal metastasis and LVI in breast cancer patients. It significantly affects the survival rate and disease recurrence of breast cancer patients. Therefore, detailed descriptions of breast edema in preoperative breast MRI may provide prognosis prediction and more intensive surveillance is needed for breast cancer patients with breast edema.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract